Adjuvant PARP Inhibition: Risk Stratification and Sequencing in High-Risk Patients

How should clinicians stratify risk in the adjuvant setting and choose between PARP inhibitors, IO, or CDK4/6 inhibitors? Drs. Iyengar and Robson unpack OlympiA data, residual disease definitions, and the evolving approach to high-risk early breast cancer.